RecruitingEarly Phase 1NCT05997043

Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease

Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease:Randomized Controlled Trial


Sponsor

Zhujiang Hospital

Enrollment

60 participants

Start Date

Aug 26, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

A randomized controlled trial is to be conducted to confirm the efficacy and safety of intramuscular injection of botulinum toxin in the treatment of Parkinson's bladder overactivity.


Eligibility

Min Age: 25 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing Botox (botulinum toxin A) injected into the bladder to treat overactive bladder (a condition causing urgency, frequent urination, and sometimes leakage) in people with Parkinson's disease. **You may be eligible if...** - You have idiopathic Parkinson's disease (the most common form, not caused by another condition) - You have overactive bladder symptoms, confirmed by a 3-day voiding diary and scoring questionnaire - You are between 25 and 80 years old - You are currently taking dopaminergic medications for Parkinson's **You may NOT be eligible if...** - You have a different form of Parkinson's (not idiopathic) - You do not have overactive bladder symptoms confirmed by assessment - You are outside the 25–80 age range - You are unable to tolerate the evaluation required for inclusion Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGoral anti-Parkinson drugs and injection of botulinum toxin

The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin

DRUGoral anti-Parkinson's drugs

The control group only took oral anti-Parkinson's drugs.


Locations(1)

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05997043


Related Trials